Trial Profile

A randomized, double-blind, placebo-controlled, proof-of-concept study assessing the effect of Fremanezumab on pain in patients with Complex Regional Pain Syndrome

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Oct 2024 New trial record
09 Aug 2024 As of January 2024, three patients have been included in the study, two of whom have been randomized. It is expected that more patients will be included in the study and undergo randomization before the IASP 2024 World Congress on Pain in August, and baseline data of these patients will be presented at the congress as per trial design presented at the 20th World Congress on Pain
09 Aug 2024 Trial design presented at the 20th World Congress on Pain

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com